Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma (Q24245643)

1

0 references

Ilana IG Greenstone

2

0 references

Vincent Masse

4

0 references

A Danish

Cochrane Database of Systematic Reviews

5

0 references

publication date

19 October 2005

0 references

published in

0 references

cites work

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Serum potassium levels, CPK-MB and ECG in children suffering asthma treated with beclomethasone or beclomethasone-salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Potential masking effects of salmeterol on airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Adult Asthma Consensus Guidelines update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Long-acting beta2-agonists for stable chronic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of long‐acting β2 agonists on exacerbation rates of asthma in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Models for estimating the number of unpublished studies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Efficacy and safety of salmeterol in childhood asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of salmeterol is independent of previously inhaled salbutamol: a clinical controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Nocturnal asthma: effect of treatment with oral sustained-release terbutaline, inhaled budesonide, and the two in combination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Clinical trials: are these your patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effects of treatment with formoterol on bronchoprotection against methacholine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

β2-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma☆☆☆★★★

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of anti-asthmatic drugs on the response to inhaled endotoxin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Innovative therapies for asthma: anti-IgE -- the future?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

The effect of anti-allergic mattress encasings on house dust mite-induced early- and late-airway reactions in asthmatic patients. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Long-acting bronchodilators in premenstrual exacerbation of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patien

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Treatment of bronchial asthma using a new adjustable combination treatment plan: Asthma Control Plan (ATACO)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Beta-adrenergic bronchodilators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromogl

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Clinical evaluation of CFC-free metered dose inhalers.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Continuing patient care with metered-dose inhalers.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Need for theophylline in severe steroid-requiring asthmatics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A double-blind comparison of inhaled budesonide, long-acting theophylline, and their combination in treatment of nocturnal asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Influence of budesonide on the response to inhaled terbutaline in children with mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol in paediatric asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Validation of an asthma quality of life diary in a clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol protects against platelet-activating factor-induced effects in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Long-acting inhaled beta2-agonists in asthma therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Effectiveness and safety of salmeterol in nonspecialist practice settings

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

What is a spontaneous pneumothorax?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of the effects of salmeterol and formoterol in patients with severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Beta(2)-agonists: déjà vu all over again: the second-generation controversy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Development of an economic model to assess the cost effectiveness of asthma management strategies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Formoterol delivered by Turbuhaler: in pediatric asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Estimation of a common effect parameter from sparse follow-up data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021

Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005535

7 January 2021